Upstream Bio Stock
HealthTechLooking to sell Upstream Bio stock or options?
Upstream Bio Inc is a biotech firm in the clinical stage, focusing on creating therapies for inflammatory ailments, particularly severe respiratory conditions. Their lead development, verekitug, is an antagonist targeting the receptor for Thymic Stromal Lymphopoietin (TSLP). This cytokine is a crucial contributor to inflammatory responses and is situated upstream of numerous signaling pathways involved in various immune-related diseases.
Maruho, Access Biotechnology, Bain Capital Life Sciences, Samsara BioCapital, Wellington Management, HBM Partners, TCG Crossover Management, Altshuler Shaham Investment House, OrbiMed, Enavate Sciences, HBM Healthcare Investments, Venrock, Omega Funds, Decheng Capital.